ArticleWorld journal of hepatology2015
Multiresistant bacterial infections in liver cirrhosis: Clinical impact and new empirical antibiotic treatment policies.
Article in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Angel or devil: the dual roles of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside in the development of liver injury based on integrating pharmacological techniques: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.World journal of gastroenterology · 2017Pooled it
- Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects.npj antimicrobials and resistance · 2024Review
- Protective role of resveratrol against VCM-induced hepatotoxicity in male wistar rats.Frontiers in pharmacology · 2023Article
- Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults.Infection & chemotherapy · 2022Review
- [Analysis of pathogenic bacteria in cirrhotic patients complicated with bacterial infection in a tertiary hospital in Xinjiang].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Clinical, Laboratory and Bacterial Profile of Spontaneous Bacterial Peritonitis in Vietnamese Patients with Liver Cirrhosis.Hepatic medicine : evidence and research · 2022Article
- Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway.JHEP reports : innovation in hepatology · 2021Article
- Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-ProducingPathogens (Basel, Switzerland) · 2021Article
- Bacterial Pathogens, Drug-Resistance Profile and Its Associated Factors from Patients with Suspected Peritonitis in Southern Ethiopia.Infection and drug resistance · 2021Article
- Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study.Experimental and therapeutic medicine · 2019Article
- Epidemiology and risk factors for multi-drug resistant hospital-acquired urinary tract infection in patients with liver cirrhosis: single center experience in Serbia.BMC infectious diseases · 2019Article
- Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies.Hepatic medicine : evidence and research · 2019Review
- Bloodstream infection due toOncotarget · 2018Article
- Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review.World journal of hepatology · 2018Review
- Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection.Oncotarget · 2018Article
- Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.World journal of hepatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, important changes have been reported regarding the epidemiology of bacterial infections in liver cirrhosis. There is an emergence of multiresistant bacteria in many European countries and also worldwide, including the United States and South Korea. The classic empirical antibiotic treatment (third-generation cephalosporins, e.g., ceftriaxone, cefotaxime or amoxicillin-clavulanic acid) is still effective in infections acquired in the community, but its failure rate in hospital acquired infections and in some health-care associated infections is high enough to ban its use in these settings. The current editorial focuses on the different epidemiology of bacterial infections in cirrhosis across countries and on its therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.